Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • IL Receptor
    (248)
  • TNF
    (83)
  • NF-κB
    (38)
  • COX
    (24)
  • Interleukin
    (21)
  • NOS
    (19)
  • Caspase
    (13)
  • ERK
    (12)
  • IκB/IKK
    (11)
  • Antifection
    (10)
Filter
Search Result
Results for "

ilreceptor

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    250
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    5
    TargetMol | Peptide_Products
  • Inhibitory Antibodies
    51
    TargetMol | Inhibitory_Antibodies
  • Natural Products
    142
    TargetMol | Natural_Products
  • Disease Modeling
    2
    TargetMol | Disease_Modeling_Products
Dupilumab
SAR-231893, REGN-668
T136661190264-60-8
Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Olamkicept
TJ-301, TJ301, FE-999301, FE999301, FE-301, FE301
T732091702282-14-1
Olamkicept (FE-301) is a soluble gp130-Fc-fusion protein that selectively inhibits interleukin 6 (IL-6) trans-signaling by binding to the soluble IL-6 receptor IL-6 complex.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Benralizumab
MEDI-563, BIW-8405
T104971044511-01-4
Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, leading to a rapid depletion of eosinophils. Benralizumab is used for severe eosinophilic asthma and can be employed to prevent exacerbations of chronic obstructive pulmonary disease.
  • Inquiry Price
Size
QTY
Reslizumab
Sch55700, DCP-835, DCP835, CEP-38072, CEP38072
T12706241473-69-8
Reslizumab (Sch 55700) is a humanized immunoglobulin G (IgG)4 κ monoclonal antibody that binds to human interleukin 5, thereby decreasing eosinophil production and survival.Reslizumab improves lung function, induces a decrease in eosinophil production and maturation, and may be used in the study of asthma.
  • Inquiry Price
Size
QTY
Ixekizumab
LY2439821
T381051143503-69-8
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM. It blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members. Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis, and psoriasis.
  • Inquiry Price
Size
QTY
Guselkumab
CNTO 1959
T383621350289-85-8
Guselkumab (CNTO 1959) is a recombinant human IgG1 monoclonal antibody targeting the IL-23p19 subunit. Guselkumab binds to human cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol L, respectively. Guselkumab can inhibit the production of cytokines downstream of IL-23 signaling pathway, and can be used in the study of psoriatic arthritis.
  • Inquiry Price
Size
QTY
Daclizumab
Zenapax, Ro 24-7375
T73689152923-56-3
Daclizumab (Zenapax) is a humanized monoclonal antibody that specifically inhibits the alpha subunit of IL-2R-HA. Daclizumab (Zenapax) can inhibit the binding of IL-2 and IL-2R-HA through specific binding to CD25. Daclizumab (Zenapax) studies multiple sclerosis.
  • Inquiry Price
Size
QTY
Canakinumab
Ilaris, ACZ 885
T73695914613-48-2
Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively. It exhibits anti-inflammatory activity by neutralizing IL-1β signaling, and it has been used for the treatment of gout and coronary artery disease.
  • Inquiry Price
Size
QTY
Tralokinumab
LP 0162, CAT-354
T767041044515-88-9
Tralokinumab is a fully human IgG4 monoclonal antibody with a high affinity for IL-13 alone. Tralokinumab's potential anti-inflammatory activity prevents IL-13 receptor interaction and subsequent downstream signaling and can be used to study atopic dermatitis (AD).
  • Inquiry Price
Size
QTY
Sarilumab
Sarilumab (anti-IL-6Rα), SAR-153191, REGN-88
T767221189541-98-7
Sarilumab (SAR-153191)is a potent interleukin-6 IL-6 receptor antagonist and a human immunoglobulin G1 monoclonal antibody. Sarilumab inhibits IL-6-mediated signaling and reduces inflammation.Sarilumab is used for the prevention and treatment of rheumatoid arthritis.
  • Inquiry Price
Size
QTY
Enokizumab
MEDI-528
T76744909875-08-7
Enokizumab (MEDI-528) is a monoclonal antibody against interleukin IL-9. Enokizumab can be used to study asthma.
  • Inquiry Price
Size
QTY
Olokizumab
CDP-6038, CDP6038
T767531007223-17-7
Olokizumab (CDP-6038) is a humanized anti-IL-6 monoclonal antibody that selectively blocks the final assembly of the IL-6 signaling complex for the study of rheumatoid arthritis (RA).
  • Inquiry Price
Size
QTY
Rolinsatamab
T767732095467-30-2
Rolinsatamab is a fully humanized selective monoclonal antibody that is a potent dual inhibitor of IL-4 and IL-13. Rolinsatamab chimeric antigen receptor sequence T cells. Rolinsatamab can be used to prevent and treat immune diseases.
  • Inquiry Price
Size
QTY
Bermekimab
MABp1
T767771401965-15-8
Bermekimab (MABp1) is a humanized monoclonal antibody against interleukin-1α (IL-1α).Bermekimab has potential anti-inflammatory activity to prevent skin inflammation.
  • Inquiry Price
Size
QTY
Risankizumab
SKYRIZI, Risankizumab rzaa, BI-655066, ABBV 066
T767781612838-76-2
Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM. Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.
  • Inquiry Price
Size
QTY
Brodalumab
LP 0160, KHK-4827, AMG-827
T767791174395-19-7
Brodalumab (AMG 827) is a human monoclonal IgG2 antibody targeting the interleukin 17 receptor (IL-17R), commonly used as an immunosuppressant in treating psoriasis.
  • Inquiry Price
Size
QTY
Tildrakizumab
SCH 900222, MK 3222
T767841326244-10-3
Tildrakizumab (SCH 900222) is a potent humanized monoclonal antibody targeting the p19 subunit of IL-23 with a Kd value of 136 pM, useful for studying psoriasis.
  • Inquiry Price
Size
QTY
Vunakizumab
Anti-Human IL17A Recombinant Antibody
T768401792181-33-9
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1].
  • Inquiry Price
Size
QTY
Nidanilimab
CAN04
T768732171061-85-9
Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. It exhibits antitumor activity by disrupting the IL1α and IL1β signaling pathways and inducing the immune system to destroy tumor cells. Nidanilimab can be used to study solid cancers, such as non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).
  • Inquiry Price
Size
QTY
Spesolimab
MAB92, BI 655130
T768842097104-58-8
Spesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. It plays a crucial role in the immune system by reducing biomarkers associated with congenital Th1 Th17 and neutrophil pathways. Spesolimab can be used to study systemic pustular psoriasis, palmar and plantar impetigo (PPP), and atopic dermatitis.
  • Inquiry Price
Size
QTY
Ordesekimab
PRV-015, AMG 714
T76892879293-15-9
Ordesekimab (AMG 714) is a human IgG1 κ-anti-IL-15 (Interleukin Related) monoclonal antibody. Ordesekimab binds competitively to IL-15, inhibiting the interaction of IL-15 with the common gamma chain of the IL-2Rβ and IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab can be used to study non-reactive celiac disease (NRCD).
  • Inquiry Price
Size
QTY
Abrezekimab
VR 942, UCB4144
T768962043952-59-4
Abrezekimab (VR 942) is composed of CDP7766, leucine, and trehalose. Abrezekimab is a humanized antibody that targets human IL-13. Abrezekimab inhibits binding to IL-13Rα1 subunit. Abrezekimab can be used to study biological disorders associated with asthma and lung disease.
  • Inquiry Price
Size
QTY
Xeligekimab
GR-1501, GR1501, GR 1501
T769532382921-73-3
Xeligekimab (GR 1501) is a fully human monoclonal antibody that selectively neutralizes IL-17A, has potential anti-inflammatory activity, and can be used to study plaque psoriasis.
  • Inquiry Price
Size
QTY
Siltuximab
CNTO-328
T76978541502-14-1
Siltuximab(CNTO-328) is a monoclonal antibody with anti-tumor activity targeting IL-6 for the study of giant lymph node hyperplasia (MCD) and COVID-19.
  • Inquiry Price
Size
QTY